Becton Dickinson & Co (WBO:BDX)
€ 210.4 -0.6 (-0.28%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.36 PB Ratio: 2.48 GF Score: 82/100

Becton Dickinson and Co at Wells Fargo Healthcare Conference Transcript

Sep 06, 2023 / 12:45PM GMT
Release Date Price: €248.5 (-3.12%)
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this fireside chat with the management team from BD. With us, we have Tom Polen, Chairman, President and CEO and Chris DelOrefice, Executive Vice President and CFO.

In terms of format, as I said, it's going to be a fireside chat. If anybody has a question they want to ask, just raise your hand. And so with that, we'll jump in.

Tom and Chris, thanks so much for being here.

Thomas E. Polen
Becton, Dickinson and Company - President, CEO & Chairman

Great to be here.

Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

So Tom, let's start with Alaris, which was cleared recently by FDA. It was obviously a very important milestone for the company. I think you said in the past it was your #1 priority. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot